Search research articles
Contact Us
Filters
Showing results (61-70 of 252) with videos related to
Page
of 26
Sort By:
Nature Reviews. Clinical Oncology
|
March 14, 2012
Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise?
Harold J Burstein
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 27, 2014
Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy
Harold J Burstein
JAMA
|
December 6, 2016
Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough?
Harold J Burstein, Deborah Schrag
JAMA Oncology
|
February 19, 2026
Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?
Carmine Valenza, Harold J Burstein
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2024
Anthracyclines in Early Breast Cancer: The Long Goodbye
Thomas Grinda, Harold J Burstein
The New England Journal of Medicine
|
July 23, 2015
Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy
Harold J Burstein, Monica Morrow
Annals of Surgical Oncology
|
April 11, 2018
How Old is Too Old? Breast Cancer Treatment in Octogenarians
Pedro Exman, Harold J Burstein
Current Treatment Options in Oncology
|
June 12, 2002
HER2 overexpressing metastatic breast cancer
David R Spigel, Harold J Burstein
Surgical Oncology Clinics of North America
|
July 13, 2010
Adjuvant hormonal therapy for early-stage breast cancer
Harold J Burstein, Jennifer J Griggs
Lancet (London, England)
|
March 8, 2011
EMBRACE, eribulin, and new realities of advanced breast cancer
Nancy U Lin, Harold J Burstein
Page
of 26
Search research articles
Search
Showing results (61-70 of 252) with videos related to
Sort By:
Page
of 26
Nature Reviews. Clinical Oncology
|
March 14, 2012
Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise?
Harold J Burstein
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 27, 2014
Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy
Harold J Burstein
JAMA
|
December 6, 2016
Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough?
Harold J Burstein, Deborah Schrag
JAMA Oncology
|
February 19, 2026
Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?
Carmine Valenza, Harold J Burstein
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2024
Anthracyclines in Early Breast Cancer: The Long Goodbye
Thomas Grinda, Harold J Burstein
The New England Journal of Medicine
|
July 23, 2015
Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy
Harold J Burstein, Monica Morrow
Annals of Surgical Oncology
|
April 11, 2018
How Old is Too Old? Breast Cancer Treatment in Octogenarians
Pedro Exman, Harold J Burstein
Current Treatment Options in Oncology
|
June 12, 2002
HER2 overexpressing metastatic breast cancer
David R Spigel, Harold J Burstein
Surgical Oncology Clinics of North America
|
July 13, 2010
Adjuvant hormonal therapy for early-stage breast cancer
Harold J Burstein, Jennifer J Griggs
Lancet (London, England)
|
March 8, 2011
EMBRACE, eribulin, and new realities of advanced breast cancer
Nancy U Lin, Harold J Burstein
Page
of 26